<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">Health</journal-id><journal-title-group><journal-title>Health</journal-title></journal-title-group><issn pub-type="epub">1949-4998</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/health.2016.811110</article-id><article-id pub-id-type="publisher-id">Health-70039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Hypertension in Adolescent
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Nataša</surname><given-names>Marčun Varda</given-names></name><xref ref-type="aff" rid="aff1"><sub>1</sub></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Pediatrics, University Medical Center Maribor, Maribor, Slovenia</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>natasa.marcunvarda@amis.net</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>08</month><year>2016</year></pub-date><volume>08</volume><issue>11</issue><fpage>1065</fpage><lpage>1074</lpage><history><date date-type="received"><day>22</day>	<month>July</month>	<year>2016</year></date><date date-type="rev-recd"><day>accepted</day>	<month>21</month>	<year>August</year>	</date><date date-type="accepted"><day>24</day>	<month>August</month>	<year>2016</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Hypertension in adolescents is, as in other patients, one of the important cardiovascular risk factors, associated with hypertension in adults and with appearance of cardiovascular complications later in life. In recent years it is in increase, in parallel with occurrence of overweight in this age group. There is mostly essential or obesity-related hypertension. It is often asymptomatic, therefore it holds true also for adolescents, that it has to be actively searched, especially in risk groups such as overweight adolescents, adolescents with positive family history or some of the other classical cardiovascular risk factors. If we have normal-weight adolescent with important hypertension or symptomatic adolescent without positive family history, the possibility of secondary hypertension has to be thinking of and extended, on possible cause focused and stepwise diagnostics performed. In this case, the treatment is etiological. Otherwise, the first-line treatment in adolescents comprises nonpharmacological treatment measures. Sometimes, because of poor nonpharmacological treatment compliance and presence of hypertensive-target organ damage, antihypertensive medications have to be introduced. However, preventive actions represent the most important task, in the form of primary and primordial prevention. In this article, diagnostic approach, prevention and treatment strategies in adolescents are shortly presented.
 
</p></abstract><kwd-group><kwd>Hypertension</kwd><kwd> Diagnostic Approach</kwd><kwd> Prevention</kwd><kwd> Treatment</kwd><kwd> Adolescent</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Hypertension is one of the most common chronic diseases in children, especially in adolescents [<xref ref-type="bibr" rid="scirp.70039-ref1">1</xref>] . In recent years, it has been increased, mainly due to a rise of obesity, having a significant impact on the level of blood pressure [BP] [<xref ref-type="bibr" rid="scirp.70039-ref2">2</xref>] . Thus, in one study of schoolchildren overweight has been observed in 27.9%, increased BP in 18.4%, and persistently elevated BP in 2.8% of included patients [<xref ref-type="bibr" rid="scirp.70039-ref3">3</xref>] . In American adolescents prehypertension or hypertension were observed in 14%, which is an important part of adolescents at risk [<xref ref-type="bibr" rid="scirp.70039-ref1">1</xref>] . In adolescents with the single measurement of BP in pre-hypertensive range, after two years hypertension was confirmed in 14% of boys and 12% of girls [<xref ref-type="bibr" rid="scirp.70039-ref4">4</xref>] . It has been assessed that the rate of progression from prehypertension to hypertension in adolescents is 7% annually [<xref ref-type="bibr" rid="scirp.70039-ref4">4</xref>] . In our population of adolescents with essential hypertension, we also found a link with overweight, as 42% of the subjects were overweight and 23% obese, respectively [<xref ref-type="bibr" rid="scirp.70039-ref5">5</xref>] . Many other studies have clearly demonstrated that hypertension also occurs in children, especially in obese, and that it is not rare [<xref ref-type="bibr" rid="scirp.70039-ref6">6</xref>] . Moreover, there is increasing evidence that it is associated with the development of hypertension and the occurrence of cardiovascular complications in adulthood, although we still do not have prospective study that would directly demonstrate the connection between hypertension in childhood and cardiovascular events later in life [<xref ref-type="bibr" rid="scirp.70039-ref7">7</xref>] - [<xref ref-type="bibr" rid="scirp.70039-ref10">10</xref>] .</p><p>In pediatrics, American recommendations for management of children and adolescents with hypertension have been published in 2004 and European ones in 2009, both needing the revision [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . They cover both the normative values as well as algorithms for diagnosis and treatment. A few years ago, our recommendations for the diagnostic approach to the child with hypertension have also been published [<xref ref-type="bibr" rid="scirp.70039-ref13">13</xref>] . We must be aware that adolescents with cardiovascular risk, which include adolescents with elevated BP, have to be actively searched, since they are generally asymptomatic. These also often apply to young people who have a significant increase in BP values and most likely secondary hypertension [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] - [<xref ref-type="bibr" rid="scirp.70039-ref13">13</xref>] . At the same time, we have to take the principles of BP measurement into account using the appropriate devices and cuffs, normative values according to gender, age and height of the adolescent, reproducibility of measurements and evidence of sustained hypertension. These has to be followed by the decision about focused etiological diagnostics, and afterwards the determination of traditional cardiovascular risk factors, co-morbidity status, hypertensive target organ damage and total cardiovascular risk score have to be performed in all young hypertensive patients [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref13">13</xref>] . Based on all these findings the decision about the proper therapy has to be made, which is primarily non-pharmacological. When cardiovascular risk is determined even in adolescents the medications are introduced, mostly angiotensin-convert- ing enzyme (ACE) inhibitors and calcium channel antagonists [<xref ref-type="bibr" rid="scirp.70039-ref14">14</xref>] . At least, as important as treatment, our work in the field of prevention of cardiovascular diseases should start in childhood [<xref ref-type="bibr" rid="scirp.70039-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref16">16</xref>] .</p></sec><sec id="s2"><title>2. Definition of Hypertension in Adolescent</title><p>The most important step in the search for adolescents with hypertension is correct measurement of BP [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . BP devices must be techically approved and the measurements made by protocol [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . The cuff size has to be adapted to growth and development of adolescents and obesity if present. Therefore, even in individuals of the same age it may be different and should cover two-thirds of upper arm [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] . If measurement using the oscillometric method of BP measurement is performed it must be confirmed with auscultatory one, with calibrated devices [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref17">17</xref>] . Another problem is the mercury device which is practically no longer produced in Europe, which necessitates the use of oscillometric devices. One important objective is to develop new exact BP devices and devices appropriate normative values [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . Most reference values for children and adolescents, gained on large samples of included subjects, were carried out using the auscultatory method, and with the increasing use of oscillometric devices the reference values for them are needed. Some of the latter have already been published [<xref ref-type="bibr" rid="scirp.70039-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref19">19</xref>] .</p><p>Furthermore, it is important to use the reference values according to gender, age and height of the child and adolescent, the definition of hypertension in children and adolescents (<xref ref-type="table" rid="table1">Table 1</xref>) and to confirm persistently elevated BP [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . Diagnostic criteria for adolescents, as well as for children, are based on percentile curves, obtained by measuring BP of healthy population and define the increased BP as a systolic and/or diastolic BP above the 95th percentile for gender, age and height, measured at least at three different occasions [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] . Because we treat adolescents, it is also necessary to know the definition of hypertension for the adult population. According to the latest recommendations the high-normal BP for adults is in the range of 130 - 139 and/or 85/89 mmHg, and hypertension, which has 3 stages, above the value of 140/90 mmHg. Recommendations also use optimal BP, which is below 120/80 mmHg [<xref ref-type="bibr" rid="scirp.70039-ref20">20</xref>] . The recommendations for children and adolescents also define high normal BP, which is more than 120/80 mmHg, and hypertension with 2 stages (<xref ref-type="table" rid="table1">Table 1</xref>) [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . In this light it is interesting to look at the results of one of the studies investigating the incidence of hypertension in 18-year old adolescents using adult criteria versus pediatric percentile curves. It was found that in the first case, the hypertension was 9%, and in the second one, 14.7% [<xref ref-type="bibr" rid="scirp.70039-ref21">21</xref>] . <xref ref-type="table" rid="table1">Table 1</xref> shows the frequency of follow-up of adolescents at each hypertension stage [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . In recent years, 24-hour ambulatory BP measurement has also been increasingly used with reference values for this form of measurement [<xref ref-type="bibr" rid="scirp.70039-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref23">23</xref>] . This is especially useful in</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Definition of elevated blood pressure (BP) in children and adolescents and recommendation for follow-up measurements and diagnostic approach [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >BP, hypertension</th><th align="center" valign="middle" >Percentiles of systolic and/or dyastolic BP</th><th align="center" valign="middle" >Follow-up measurements of BP and diagnostic approach</th></tr></thead><tr><td align="center" valign="middle" >Normal BP</td><td align="center" valign="middle" >&lt;90<sup>th</sup> percentile</td><td align="center" valign="middle" >During routine systematic and other pediatric examinations</td></tr><tr><td align="center" valign="middle" >High-normal BP</td><td align="center" valign="middle" >≥90<sup>th</sup> to &lt;95<sup>th</sup> percentile ≥120/80, in adolescents, even if the value of BP is bellow 90<sup>th</sup> percentile</td><td align="center" valign="middle" >After 6 months</td></tr><tr><td align="center" valign="middle" >Stage 1 hypertension</td><td align="center" valign="middle" >Between 95<sup>th</sup> and 99<sup>th</sup> percentile plus 5 mmHg</td><td align="center" valign="middle" >After 1 to 2 weeks or before, if the patient is symptomatic; if the BP is persistently elevated, diagnostics has to be performed in 1 month</td></tr><tr><td align="center" valign="middle" >Stage 2 hypertension</td><td align="center" valign="middle" >&gt;99<sup>th</sup> percentile plus 5 mmHg</td><td align="center" valign="middle" >Diagnostics and treatment in 1 week or immediately, if the patient is symptomatic</td></tr></tbody></table></table-wrap><p>determining white coat hypertension and masked hypertension, to monitor the effectiveness of pharmacological treatment and BP variability as well as in research purposes [<xref ref-type="bibr" rid="scirp.70039-ref22">22</xref>] . There is evidence that it better predicts cardiovascular events and the risk of target organ damage as the standard methods of measurement [<xref ref-type="bibr" rid="scirp.70039-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref25">25</xref>] .</p></sec><sec id="s3"><title>3. Diagnostic Evaluation of Hypertension in Adolescent</title><p>Since the recommendations for BP measurements from the third year of age as a part of the routine preventive management of all children, it is possible to actively search for children at risk and thus adolescents, which are often, with significant hypertension, completely asymptomatic [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . When in adolescent persistently elevated BP is confirmed, he is classified, according to the clinical features, into one of two groups of patients. Most young people belong to the group of patients with mildly elevated BP, who are mostly asymptomatic, without changes in hypertensive target organs and the possible cardiovascular complications later in life [<xref ref-type="bibr" rid="scirp.70039-ref13">13</xref>] . These are adolescents with essential hypertension or obesity-related hypertension. Sometimes, even in this group a clinical suspicion of one of the secondary forms of hypertension is made, especially if we are dealing with a normally nourished, symptomatic adolescent with significant hypertension and a negative family history of cardiovascular diseases. The most common causes of elevated BP in adolescent patients are essential hypertension, and obesity-related hypertension, but iatrogenic causes, consumption of certain food supplements and drugs, renal parenchymal disease, renal vascular disease, endocrine causes and coarctation of the aorta can be diagnosed as well [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] - [<xref ref-type="bibr" rid="scirp.70039-ref13">13</xref>] . Most of them should be suspected with accurate history and good clinical examination [<xref ref-type="bibr" rid="scirp.70039-ref26">26</xref>] . Diagnostics must be stepwise [<xref ref-type="bibr" rid="scirp.70039-ref26">26</xref>] . Most adolescents need only investigations of Step 1, which are performed in all patients (routine tests) (<xref ref-type="fig" rid="fig1">Figure 1</xref>) [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . They are needed for hypertensive target organ damage and traditional cardiovascular risk factors determination. Consideration should be given to concomitant diseases and the cardiovascular risk evaluation [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref13">13</xref>] . Hypertensive target organ damage status is one of the important parts of the diagnostics, as it gives us insight into the initial effects of hypertension in adolescents, but also serves as an intermediate objective of successful treatment monitoring [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref27">27</xref>] . Investigations of recent years show that the initial damage of target organs is present more often than it has been thought, even in adolescents with mildly elevated BP, and is, at least in the early stages, reversible [<xref ref-type="bibr" rid="scirp.70039-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref29">29</xref>] . In recent years intensive research has been performed investigating the importance of the earliest indicators of target organ damage, which includes measurement of intima media thickness of the carotid artery, pulse wave velocity measurement of vessels, microalbuminuria [<xref ref-type="bibr" rid="scirp.70039-ref29">29</xref>] - [<xref ref-type="bibr" rid="scirp.70039-ref31">31</xref>] . Further research is needed in the field of early indicators of damage of target organs and early markers of cardiovascular risks, especially in the area of potential genetic factors [<xref ref-type="bibr" rid="scirp.70039-ref32">32</xref>] .</p></sec><sec id="s4"><title>4. Prevention of Hypertension in Adolescent</title><p>Without a doubt, the most important part of management of adolescents in terms of cardiovascular health is prevention. The measures of primary prevention are used to prevent the occurrence of cardiovascular disease through the reduction of known cardiovascular risk factors. Secondary prevention includes measures for the</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Diagnostics of adolescents with elevated blood pressure [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref13">13</xref>] </title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/6-8203787x6.png"/></fig><p>early detection and treatment of preclinical changes and with that appropriately control the progression of the disease [<xref ref-type="bibr" rid="scirp.70039-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref16">16</xref>] . In addition to primary and secondary prevention in recent times the importance of so-called primordial prevention has been increasingly recognized as a new important mechanism for improving cardiovascular health. The term refers to the way of maintaining normal levels of known cardiovascular risk factors, including the BP, from childhood to adulthood [<xref ref-type="bibr" rid="scirp.70039-ref15">15</xref>] . It is derived from the principles of a healthy lifestyle, which does not allow the occurrence of cardiovascular risk factors and as such represents the best way to lower cardiovascular risk [<xref ref-type="bibr" rid="scirp.70039-ref16">16</xref>] . Few recent research studies have shown that individuals who maintain an ideal profile of cardiovascular risk factors from youth to middle age, have significantly reduced risk of all cardiovascular events and a better quality of life in later life [<xref ref-type="bibr" rid="scirp.70039-ref33">33</xref>] . In addition to focus on maintaining good health, it is necessary to search for individuals with increased cardiovascular risks, which have, due to inappropriate lifestyle, genetic predisposition or diseases, a greater likelihood of early cardiovascular aging [<xref ref-type="bibr" rid="scirp.70039-ref34">34</xref>] . These clearly include adolescents with hypertension, especially adipose ones. After identification of adolescents at risk there is urgent need to initiate appropriate treatment and to follow-up them regularly. Better detection of young hypertensive patients is undoubtedly enabled by regular measurements of BP from the third year onwards, as well as by search for potential patients through regular visits to personal pediatricians, including adipose adolescents and those with a positive family history of cardiovascular disease [<xref ref-type="bibr" rid="scirp.70039-ref34">34</xref>] . It has to be stressed that cardiovascular prevention and active search for adolescents at risk are not only the task of health workers, but of the entire state and civil society [<xref ref-type="bibr" rid="scirp.70039-ref35">35</xref>] . Healthy lifestyle and self-care are the duties of each individual, but we must encourage them at all levels, in families, schools, local communities, relevant ministries, with the support of the public media [<xref ref-type="bibr" rid="scirp.70039-ref35">35</xref>] . Moreover, there is a need for a global approach to the problem of cardiovascular health with long-term goal to limit the cardiovascular disease epidemic [<xref ref-type="bibr" rid="scirp.70039-ref36">36</xref>] . Recently recommendations on the preservation of cardiovascular health by age and developmental pediatric groups have also been published [<xref ref-type="bibr" rid="scirp.70039-ref37">37</xref>] .</p></sec><sec id="s5"><title>5. Treatment of Hypertension in Adolescent</title><p>The main goal of the treatment of hypertension in adolescence is to reduce the cardiovascular risk associated with persistently elevated BP [<xref ref-type="bibr" rid="scirp.70039-ref38">38</xref>] . Rarely, emergency treatment is required due to very high values of BP and symptomatology. In this case, the use of short-acting intravenous antihypertensive agents is needed, with careful monitoring of the cardiovascular system, preferably in an intensive care unit [<xref ref-type="bibr" rid="scirp.70039-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref40">40</xref>] . The basis of treatment represent non-pharmacological treatment measures, introduced in all patients, including those who require pharmacological treatment. Lifestyle change and a healthy lifestyle promotion with a healthy diet, improved quality of sleep, regular physical activity and limited sedentary activities represent the first line therapy [<xref ref-type="bibr" rid="scirp.70039-ref41">41</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref42">42</xref>] . Dietary changes include a reduction in fat and cholesterol, especially saturated fat, reduction of the intake of soft drinks and fast food, increased intake of fresh fruits, vegetables and whole grains, quantitative restrictions of meals and drinks, limitation of discharging meals. Thus, randomized study DASH (Dietary Approaches to Stop Hypertension) in a group of adolescents with hypertension has shown, that the increase in fruit and vegetable intake and limitation of the fat intake was associated with a clear BP reduction [<xref ref-type="bibr" rid="scirp.70039-ref43">43</xref>] . The best results were achieved by a combination of modified diet and regular physical activity. It has also been shown that a moderate reduction in salt intake lowers the level of BP [<xref ref-type="bibr" rid="scirp.70039-ref44">44</xref>] . Further significant reduction of BP has been achieved by physical activity [<xref ref-type="bibr" rid="scirp.70039-ref45">45</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref46">46</xref>] . At least 60 minutes of moderate to intensive physical activity daily are recommended as well as limitation of sedentary activities to less than two hours per day [<xref ref-type="bibr" rid="scirp.70039-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref42">42</xref>] .</p><p>In adolescents, the basis of treatment as a rule is non-pharmacological treatment. Indications for the introduction of drugs are symptomatic hypertension, presence of hypertensive target organ damage, secondary hypertension, hypertension of stage 2, presence of diabetes, persistent hypertension despite non-pharmacological measures [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . Treatment algorithm is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . At this point it should be noted that long-term consequences of untreated hypertension in otherwise healthy and asymptomatic adolescents are not known [<xref ref-type="bibr" rid="scirp.70039-ref47">47</xref>] . It is also not clear if there are some long-term effects of antihypertensive drugs on growth and development [<xref ref-type="bibr" rid="scirp.70039-ref11">11</xref>] . On the other hand, it has been proven that with the effective treatment hypertensive end-organ damage is reversible [<xref ref-type="bibr" rid="scirp.70039-ref48">48</xref>] . In recent years, quite a lot clinical research was performed also in children and adolescents on the efficacy and safety of antihypertensive drugs, as well as comparisons between different groups of antihypertensive medications [<xref ref-type="bibr" rid="scirp.70039-ref49">49</xref>] - [<xref ref-type="bibr" rid="scirp.70039-ref53">53</xref>] . Anyway, we still have the problem of the indications for use in small children [<xref ref-type="bibr" rid="scirp.70039-ref54">54</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref55">55</xref>] . Drug classes with individual representatives, initial doses and maximum doses, are shown in <xref ref-type="table" rid="table2">Table 2</xref> [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref38">38</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref56">56</xref>] . Among them, the most commonly used medications are those in the first five groups, in particular ACE inhibitors and calcium channel antagonists [<xref ref-type="bibr" rid="scirp.70039-ref14">14</xref>] . Dosage for adults should not be overcome [<xref ref-type="bibr" rid="scirp.70039-ref38">38</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref56">56</xref>] . In some clinical situations, depending on the pathophysiological mechanism, a certain class of antihypertensive agent is preferably recommended (<xref ref-type="table" rid="table3">Table 3</xref>) [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . The target value of BP also depends on the clinical condition (<xref ref-type="table" rid="table4">Table 4</xref>), although additional studies to confirm these values are needed [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . Sometimes for BP regulation in adolescents more antihypertensive drugs are needed, while we prefer a combination with complementary mechanisms of action. In our hypertensive adolescents more drugs have been introduced in 15.8% of all patients, treated pharmacologically. The drugs were introduced in one third of investigated patients [<xref ref-type="bibr" rid="scirp.70039-ref57">57</xref>] . In overweight adolescents with</p><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Treatment of child and adolescent with elevated blood pressure (adapted according to ref. [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] )</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/6-8203787x7.png"/></fig><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Classes and representatives of antihypertensive medications and doses for children and adolescents, according to weight, with maximum doses (adapted according to ref. [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref38">38</xref>] and [<xref ref-type="bibr" rid="scirp.70039-ref56">56</xref>] )</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Class</th><th align="center" valign="middle" >Medication</th><th align="center" valign="middle" >Dose</th><th align="center" valign="middle" >Interval</th><th align="center" valign="middle" >Maximum dose</th></tr></thead><tr><td align="center" valign="middle" >Diuretics</td><td align="center" valign="middle" >Amiloride Chlorthalidone Furosemide Hydrochloro-thiazide Chlorothiazide</td><td align="center" valign="middle" >0.4 - 0.6 mg/kg/day 0.3 mg/kg/day 0.5 - 2.0 mg/kg/dose 0.5 - 1.0 mg/kg/day 10 mg/kg/day</td><td align="center" valign="middle" >q.d. q.d. q.d.-b.d. q.d.-b.d. b.d.</td><td align="center" valign="middle" >20 mg/day 50 mg/day 6 mg/kg/day 50 mg/day 1 g/day</td></tr><tr><td align="center" valign="middle" >Beta-adrenergic blockers</td><td align="center" valign="middle" >Atenolol Metoprolol Propranolol Bisoprolol</td><td align="center" valign="middle" >0.5 - 1.0 mg/kg/day 0.5 - 1.0 mg/kg/day 1.0 mg/kg/day 0.2 mg/kg/day</td><td align="center" valign="middle" >q.d.-b.d. q.d. b.d.-t.d. q.d.</td><td align="center" valign="middle" >100 mg/day 200 mg/day 320 mg/day 10 mg/day</td></tr><tr><td align="center" valign="middle" >Chalcium channel antagonists</td><td align="center" valign="middle" >Amlodipine Felodipine Nifedipine (ER)</td><td align="center" valign="middle" >0.06 - 0.3 mg/kg/day 2.5 mg/day 0.25 - 0.50 mg/kg/day</td><td align="center" valign="middle" >q.d. q.d. q.d.-b.d.</td><td align="center" valign="middle" >10 mg/day 10 mg/day 120 mg/day</td></tr><tr><td align="center" valign="middle" >Angiotensin-converting enzyme inhibitors</td><td align="center" valign="middle" >Captopril Enalapril Fosinopril Lisinopril Ramipril</td><td align="center" valign="middle" >0.3 - 0.5 mg/kg/day 0.08 - 0.60 mg/kg/day 0.1 - 0.6 mg/kg/day 0.08 - 0.60 mg/kg/day 2.5 mg/day</td><td align="center" valign="middle" >b.d.-t.d. q.d. q.d. q.d. q.d.</td><td align="center" valign="middle" >450 mg/day 40 mg/day 40 mg/day 40 mg/day 20 mg/day</td></tr><tr><td align="center" valign="middle" >Angiotensin-receptor blockers</td><td align="center" valign="middle" >Candesartan Irbesartan Losartan Valsartan</td><td align="center" valign="middle" >0.16 - 0.50 mg/kg/day 75 - 150 mg/day 0.75 - 1.44 mg/kg/day 2 mg/kg/day</td><td align="center" valign="middle" >q.d. q.d. q.d. q.d.</td><td align="center" valign="middle" >32 mg/day 300 mg/day 100 mg/day 320 mg/day</td></tr><tr><td align="center" valign="middle" >Alpha- and beta-adrenergic blockers</td><td align="center" valign="middle" >Labetalol Carvedilol</td><td align="center" valign="middle" >2 - 3 mg/kg/day 0.1 mg/kg/dose</td><td align="center" valign="middle" >b.d. b.d.</td><td align="center" valign="middle" >1.2 g/day 50 mg/day</td></tr><tr><td align="center" valign="middle" >Aldosterone-receptor blockers</td><td align="center" valign="middle" >Eplerenone Spironolactone</td><td align="center" valign="middle" >25 - 50 mg/day 1 mg/kg/day</td><td align="center" valign="middle" >q.d.-b.d. q.d.-b.d.</td><td align="center" valign="middle" >100 mg/day 100 mg/day</td></tr><tr><td align="center" valign="middle" >Central alpha-agonists</td><td align="center" valign="middle" >Clonidine Methyldopa</td><td align="center" valign="middle" >5 - 10 μg/kg/day 5 mg/kg/day</td><td align="center" valign="middle" >b.d.-t.d. b.d.-f.d.</td><td align="center" valign="middle" >0.9 mg/day 3 g/day</td></tr><tr><td align="center" valign="middle" >Peripheral alpha-adrenergic blockers</td><td align="center" valign="middle" >Doxazosin Prazosin Terazosin</td><td align="center" valign="middle" >1 mg/day 0.05 - 0.1 mg/kg/day 1 mg/day</td><td align="center" valign="middle" >f.d. t.d. q.d.</td><td align="center" valign="middle" >4 mg/day 0.5 mg/kg/day 20 mg/day</td></tr><tr><td align="center" valign="middle" >Vasodilators</td><td align="center" valign="middle" >Hydralazine Minoxidil</td><td align="center" valign="middle" >0.25 mg/kg/dose 0.1 - 0.2 mg/kg/day</td><td align="center" valign="middle" >t.d.-f.d b.d.-t.d.</td><td align="center" valign="middle" >200 mg/day 50 mg/day</td></tr></tbody></table></table-wrap><p>q.d.―once daily, b.d.―twice daily, t.d.―three times daily, f.d.―four times daily, ER―extended release.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> First choice of antihypertensive medication in adolescent with specific disease and hypertension [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Clinical condition</th><th align="center" valign="middle" >First choice of antihypertensive medication</th></tr></thead><tr><td align="center" valign="middle" >Without any other disease</td><td align="center" valign="middle" >Drug from any class</td></tr><tr><td align="center" valign="middle" >Chronic kidney disease</td><td align="center" valign="middle" >ACEI/ARB</td></tr><tr><td align="center" valign="middle" >Migraine</td><td align="center" valign="middle" >Beta blockers, calcium channel antagonists</td></tr><tr><td align="center" valign="middle" >Obesity</td><td align="center" valign="middle" >ACEI</td></tr><tr><td align="center" valign="middle" >Coarctation of aorta</td><td align="center" valign="middle" >Beta blockers</td></tr><tr><td align="center" valign="middle" >Diabetes mellitus</td><td align="center" valign="middle" >ACEI/ARB</td></tr><tr><td align="center" valign="middle" >Chronic kidney failure</td><td align="center" valign="middle" >Diuretics</td></tr><tr><td align="center" valign="middle" >Hyperaldosteronism</td><td align="center" valign="middle" >Diuretics</td></tr><tr><td align="center" valign="middle" >Congestive heart failure</td><td align="center" valign="middle" >Beta blockers, ACEI/ARB, loop-acting diuretics</td></tr><tr><td align="center" valign="middle" >Kidney transplantation</td><td align="center" valign="middle" >Calcium channel antagonists</td></tr></tbody></table></table-wrap><p>ACEI―angiotensin-converting enzyme inhibitors, ARB―angiotensin-receptor blockers.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Blood pressure targets in different groups of patients [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Patients</th><th align="center" valign="middle" >Blood pressure target</th></tr></thead><tr><td align="center" valign="middle" >Uncomplicated essential hypertension</td><td align="center" valign="middle" >&lt;95<sup>th</sup> percentile for sex, age and height</td></tr><tr><td align="center" valign="middle" >Secondary hypertension, diabetes mellitus, hypertensive target-organ damage</td><td align="center" valign="middle" >&lt;90<sup>th</sup> percentile for sex, age and height</td></tr><tr><td align="center" valign="middle" >Chronic kidney disease without proteinuria</td><td align="center" valign="middle" >&lt;75<sup>th</sup> percentile for sex, age and height</td></tr><tr><td align="center" valign="middle" >Chronic kidney disease with proteinuria</td><td align="center" valign="middle" >&lt;50<sup>th</sup> percentile for sex, age and height</td></tr></tbody></table></table-wrap><p>successful non-pharmacological treatment withdrawal of medications is possible (“step-down” treatment). At that time the reversibility of changes in hypertensive target organ damage has to be taken into account [<xref ref-type="bibr" rid="scirp.70039-ref12">12</xref>] . Furthermore, it has been found out that improved therapies in children have potential for preventing or ameliorating early cardiovascular disease [<xref ref-type="bibr" rid="scirp.70039-ref58">58</xref>] .</p><p>At the end, the problem of poor treatment compliance of some young people has to be mentioned, especially for non-pharmacological treatments. Even medications are often omitted [<xref ref-type="bibr" rid="scirp.70039-ref59">59</xref>] [<xref ref-type="bibr" rid="scirp.70039-ref60">60</xref>] . Therefore, in adolescents follow-up is of utmost importance, with continuous education, interpretation of the nature of the disease, its long-term consequences, the necessity of treatment [<xref ref-type="bibr" rid="scirp.70039-ref61">61</xref>] . They need to be motivated for treatment, continuously educated and promoted for a healthy lifestyle. It is important to work with the entire family.</p></sec><sec id="s6"><title>6. Conclusion</title><p>Hypertension, one of the major cardiovascular risk factors, often also occurs in adolescents. With the introduction of routine measurement of BP of healthy children in pediatric healthcare and the active search for high-risk groups, patients with asymptomatic disease can be detected and appropriately diagnosed and treated, which has a long-term positive effects on cardiovascular health. The preventive action is equally important, in particular with the ever-increasing occurrence of obesity and related diseases. Treatment of adolescents is primarily non- pharmacological, but sometimes also requires the introduction of drugs.</p></sec><sec id="s7"><title>Cite this paper</title><p>Nataša Marčun Varda, (2016) Hypertension in Adolescent. Health,08,1065-1074. doi: 10.4236/health.2016.811110</p></sec></body><back><ref-list><title>References</title><ref id="scirp.70039-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">May, A.L., Kuklina, E.V. and Yoon, P.W. (2012) Prevalence of Cardiovascular Disease Risk Factors among US Adolescents, 1999-2008. Pediatrics, 129, 1035-1041. http://dx.doi.org/10.1542/peds.2011-1082</mixed-citation></ref><ref id="scirp.70039-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rao, G. (2016) Diagnosis, Epidemiology, and Management of Hypertension in Children. Pediatrics, 138, e20153616.http://dx.doi.org/10.1542/peds.2015-3616</mixed-citation></ref><ref id="scirp.70039-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Eakin, M.N., Brady, T., Kandasamy, V., Fivush, B. and Riekert, K.A. (2013) Disparities in Antihypertensive Medication Adherence in Adolescents. Pediatric Nephrology, 28, 1267-1273.http://dx.doi.org/10.1007/s00467-013-2455-2</mixed-citation></ref><ref id="scirp.70039-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Osterberg, L. and Blaschke, T. (2005) Adherence to Medication. New England Journal of Medicine, 353, 487-497.http://dx.doi.org/10.1056/NEJMra050100</mixed-citation></ref><ref id="scirp.70039-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Santi, M., Simonetti, B.G., Leoni-Foglia, C.F., Bianchetti, M.G. and Simonetti, G.D. (2015) Arterial Hypertension in Children. Current Opinion in Cardiology, 30, 403-410. http://dx.doi.org/10.1097/HCO.0000000000000191</mixed-citation></ref><ref id="scirp.70039-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Marcun Varda, N. and Gregoric, A. (2011) Hypertensive Target Organ Damage and Antihypertensive Treatment in Children with Essential Hypertension. Pediatric Nephrology, 26, 1726.</mixed-citation></ref><ref id="scirp.70039-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Flynn, J.T. (2011) Management of Hypertension in the Young: Role of Antihypertensive Medications. Journal of Cardiovascular Pharmacology, 58, 111-120. http://dx.doi.org/10.1097/FJC.0b013e31820d1b89</mixed-citation></ref><ref id="scirp.70039-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Schaefer, F., van de Walle, J., Zurowska, A., Gimpel, C., van Hoeck, K., Drozdz, D., et al. and Candesartan in Children with Hypertension Investigators (2010) Efficacy, Safety and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Children from 1 to Less than 6 Years of Age. Journal of Hypertension, 28, 1083-1090.http://dx.doi.org/10.1097/HJH.0b013e328336b86b</mixed-citation></ref><ref id="scirp.70039-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Flynn, J.T., Meyers, K.E., Neto, J.P., de Paula, M.R., Zurowska, A., Bagga, A., et al. (2008) Efficacy and Safety of the Angiotensin Receptor Blocker Valsartan in Children with Hypertension Aged 1 to 5 Years. Hypertension, 52, 222-228.http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.111054</mixed-citation></ref><ref id="scirp.70039-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Chaturvedi, S., Lipszyc, D.H., Licht, C., Craig, J.C. and Parekh, R.S. (2014) Cochrane in Context: Pharmacological Interventions for Hypertension in Children. Evidence Based Child Health, 9, 581-583. http://dx.doi.org/10.1002/ebch.1975</mixed-citation></ref><ref id="scirp.70039-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Schaefer, F., Litwin, M., Zachwieja, J., Zurowska, A., Turi, S., Grosso, A., et al. (2011) Efficacy and Safety of Valsartan Compared to Enalapril in Hypertensive Children. A 12-Week, Randomized, Double-Blind, Parallel-Group Study. Journal of Hypertension, 29, 2484-2490. http://dx.doi.org/10.1097/HJH.0b013e32834c625c</mixed-citation></ref><ref id="scirp.70039-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Li, J.S., Flynn, J.T., Portman, R., Davis, I., Ogawa, M., Shi, H., Pressler, M.L., et al. (2010) The Efficacy and Safety of the Novel Aldosterone Antagonist Eplerenone in Children with Hypertension: A Randomized, Double-Blind, Dose-Response Study. Journal of Pediatrics, 157, 282-287. http://dx.doi.org/10.1016/j.jpeds.2010.02.042</mixed-citation></ref><ref id="scirp.70039-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Herder, S.D., Weber, E., Winkemann, A., Herder, E. and Morck, H. (2010) Efficacy and Safety of Angiotensin II Receptor Type 1 Antagonists in Children and Adolescents. Pediatric Nephrology, 25, 801-811.http://dx.doi.org/10.1007/s00467-009-1346-z</mixed-citation></ref><ref id="scirp.70039-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Flynn, J.T. (2011) Not Ready for Prime Time: Aliskiren for Treatment of Hypertension or Proteinuria in Children. Pediatric Nephrology, 26, 491-492. http://dx.doi.org/10.1007/s00467-010-1726-4</mixed-citation></ref><ref id="scirp.70039-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kupferman, J.C., Paterno, K., Mahgerefteh, J., Pagala, M., Golden, M., Lytrivi, I.D., et al. (2010) Improvement of Left Ventricular Mass with Antihy-pertensive Therapy in Children with Hypertension. Pediatric Nephrology, 25, 1513-1518. http://dx.doi.org/10.1007/s00467-010-1511-4</mixed-citation></ref><ref id="scirp.70039-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Flynn, J.T. (2009) Hypertension in the Young: Epidemiology, Sequelae and Therapy. Nephrology Dialysis Transplantation, 24, 370-375. http://dx.doi.org/10.1093/ndt/gfn597</mixed-citation></ref><ref id="scirp.70039-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Rocchini, A.P., Katch, V., Anderson, J., Hinderliter, J., Becque, D., Martin, M. and Marks, C. (1988) Blood Pressure in Obese Adolescents: Effect of Weight Loss. Pediatrics, 82, 16-23.</mixed-citation></ref><ref id="scirp.70039-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Litwin, M., Trelewicz, J., Wawer, Z., Antoniewicz, J., Wierzbicka, A., Rajszys, P., et al. (2004) Intima-Media Thickness and Arterial Elasticity in Hypertensive Children: Controlled Study. Pediatric Nephrology, 19, 767-774.http://dx.doi.org/10.1007/s00467-004-1480-6</mixed-citation></ref><ref id="scirp.70039-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lande, M.B., Carson, N.L., Roy, J. and Meagher, C.C. (2006) Effects of Childhood Primary Hypertension on Carotid Intima Media Thickness: A Matched Controlled Study.Hypertension, 48, 40-44.http://dx.doi.org/10.1161/01.HYP.0000227029.10536.e8</mixed-citation></ref><ref id="scirp.70039-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Assadi, F. (2007) Effect of Microalbuminuria Lowering on Regression of Left Ventricular Hypertrophy in Children and Adolescents with Essential Hypertension. Pediatric Cardiology, 28, 27-33.http://dx.doi.org/10.1007/s00246-006-1390-4</mixed-citation></ref><ref id="scirp.70039-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Sladowska-Kozlowska, J., Litwin, M., Niemirska, A., Wierzbicka, A., Wawer, Z.T. and Janas, R. (2011) Change in Left Ventricular Geometry during Antihypertensive Treatment in Children with Primary Hypertension. Pediatric Nephrology, 26, 2201-2209. http://dx.doi.org/10.1007/s00467-011-1916-8</mixed-citation></ref><ref id="scirp.70039-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Litwin, M., Niemirska, A., Sladowska-Kozlowska, J., Wierzbicka, A., Janas, R., Wawer, Z.T., et al. (2010) Regression of Target Organ Damage in Children and Adolescents with Primary Hypertension. Pediatric Nephrology, 25, 2489- 2499. http://dx.doi.org/10.1007/s00467-010-1626-7</mixed-citation></ref><ref id="scirp.70039-ref23"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Marcun Varda</surname><given-names> N. </given-names></name>,<etal>et al</etal>. (<year>2012</year>)<article-title>Diagnostic Evaluation of the Child and Adolescent with Hypertension</article-title><source> Slovenska Pediatrija</source><volume> 19</volume>,<fpage> 276</fpage>-<lpage>285</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.70039-ref24"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Belsha</surname><given-names> C.W. </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>Ambulatory Blood Pressure Monitor-ing and Hypertensive Target-Organ Damage in Children</article-title><source> Blood Pressure Monitoring</source><volume> 4</volume>,<fpage> 161</fpage>-<lpage>164</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.70039-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Metoki, H., Ohkubo, T., Kikuya, M., Asayama, K., Obara, T., Hara, A., et al. (2006) Prognostic Significance of Night-Time, Early Morning, and Daytime Blood Pressures on the Risk of Cerebrovascular and Cardiovascular Mortality: The Ohasama Study. Journal of Hypertension, 24, 1841-1848. http://dx.doi.org/10.1097/01.hjh.0000242409.65783.fb</mixed-citation></ref><ref id="scirp.70039-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Soergl, M., Kirschstein, M., Busch, C., Danne, T., Gellermann, J., Holl, R., et al. (1997) Oscillometric Twenty-Four-Hour Ambulatory Blood Pressure Values in Healthy Children and Adolescents: A Multicenter Trial Including 1141 Subjects. Journal of Pediatrics, 130, 178-184. http://dx.doi.org/10.1016/S0022-3476(97)70340-8</mixed-citation></ref><ref id="scirp.70039-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Simckes, A.M., Srivastava, T. and Alon, U.S. (2002) Ambulatory Blood Pressure Monitoring in Children and Adolescents. Clinical Pediatrics, 41, 549-564. http://dx.doi.org/10.1177/000992280204100801</mixed-citation></ref><ref id="scirp.70039-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Symonides, B., Jedrusik, P., Artyszuk, L., Grybos, A., Dziliński, P. and Gaciong, Z. (2010) Different Diagnostic Criteria Significantly Affect the Rates of Hypertension in 18-Year-Old High School Students. Archives of Medical Science, 6, 689-694. http://dx.doi.org/10.5114/aoms.2010.17082</mixed-citation></ref><ref id="scirp.70039-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mancia, G., Fagard, R., Narkiewicz, K., Redán, J., Zanchetti, A., Bohm, M., et al. (2013) 2013 Practice Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. Journal of Hypertension, 31, 1925-1938. http://dx.doi.org/10.1097/HJH.0b013e328364ca4c</mixed-citation></ref><ref id="scirp.70039-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Kulaga, Z., Litwin, M., Grajda, A., Kulaga, K., Gurzkowska, B., Gózdz, M., et al. and OLAF Study Group (2012) Oscillometric Blood Pressure Percentiles for Polish Normal-Weight School-Aged Children and Adolescents. Journal of Hypertension, 30, 1942-1954. http://dx.doi.org/10.1097/HJH.0b013e328356abad</mixed-citation></ref><ref id="scirp.70039-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Neu-hauser, H.K., Thamm, M., Ellert, U., Hense, H.W. and Rosario, A.S. (2011) Blood Pressure Percentiles by Age and Height from Nonoverweight Children and Adolescents in Germany. Pediatrics, 127, e978-e988.http://dx.doi.org/10.1542/peds.2010-1290</mixed-citation></ref><ref id="scirp.70039-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Dabl Educational Trust (2016) Blood Pressure Monitors—Validations, Papers and Reviews. http://www.dableducational.org/</mixed-citation></ref><ref id="scirp.70039-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Kones, R. (2011) Primary Prevention of Coronary Heart Disease: Integration of New Data, Evolving Views, Revised Goals, and Role of Rosuvastatin in Management. A Comprehensive Survey. Drug Design, Development and Therapy, 5, 325-380. http://dx.doi.org/10.2147/DDDT.S14934</mixed-citation></ref><ref id="scirp.70039-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Capwell, S. and Lloyd-Jones, D.M. (2010) Optimal Cardiovascular Prevention Strategies for the 21st Century. JAMA, 304, 2057-2058. http://dx.doi.org/10.1001/jama.2010.1641</mixed-citation></ref><ref id="scirp.70039-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Woroniecki, R.P. and Flynn, J.T. (2005) How Are Hypertensive Children Evaluated and Managed? A Survey of North American Pediatric Nephrologists. Pediatric Nephrology, 20, 791-797. http://dx.doi.org/10.1007/s00467-004-1804-6</mixed-citation></ref><ref id="scirp.70039-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Varda, N.M. and Gregoric, A. (2005) A Diagnostic Approach for the Child with Hypertension. Pediatric Nephrology, 20, 499-506. http://dx.doi.org/10.1007/s00467-004-1737-0</mixed-citation></ref><ref id="scirp.70039-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Lurbe, E., Cifkova, R., Cruickshank Kennedy, J., Dillon, M.J., Ferreira, I., Invitti, C., et al. (2009) Management of High Blood Pressure in Children and Adolescents: Recommendations of the European Society of Hypertension. Journal of Hypertension, 27, 1719-1742. http://dx.doi.org/10.1097/HJH.0b013e32832f4f6b</mixed-citation></ref><ref id="scirp.70039-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics, 144, 555-576.</mixed-citation></ref><ref id="scirp.70039-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Sundstrom, J., Neovius, M., Tynelius, P. and Rasmussen, F. (2011) Association of Blood Pressure in Late Adolescence with Subsequent Mortality: Cohort Study of Swedish Male Conscripts. British Medical Journal, 342, d643. http://dx.doi.org/10.1136/bmj.d643</mixed-citation></ref><ref id="scirp.70039-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Franks, P.W., Hanson, R.L., Knowler, W.C., Sievers, M.L., Bennett, P.H. and Looker, H.C. (2010) Childhood Obesity, Other Cardiovascular Risk Factors, and Premature Death. New England Journal of Medicine, 362, 485-493. http://dx.doi.org/10.1056/NEJMoa0904130</mixed-citation></ref><ref id="scirp.70039-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Lawes, C.M., Vander Hoorn, S., Law, M.R., Elliott, P., MacMahon, S. and Rodgers, A. (2006) Blood Pressure and the Global Burden of Disease 2000. Part II: Estimates of Attributable Burden. Journal of Hypertension, 24, 423-430. http://dx.doi.org/10.1097/01.hjh.0000209973.67746.f0</mixed-citation></ref><ref id="scirp.70039-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X. and Wang, Y. (2008) Tracking of Blood Pressure from Child-hood to Adulthood: A Systematic Review and Meta-Regression Analysis. Circulation, 117, 3171-3180. http://dx.doi.org/10.1161/CIRCULATIONAHA.107.730366</mixed-citation></ref><ref id="scirp.70039-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Sorof, J.M., Lai, D., Turner, J., Poffenburger, T. and Portman, R.J. (2004) Overweight, Ethnicity, and the Prevalence of Hypertenison in School-Aged Children. Pediatrics, 113, 475-482. http://dx.doi.org/10.1542/peds.113.3.475</mixed-citation></ref><ref id="scirp.70039-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Marcun Varda, N. (2006) The Role of Some Genetic Factors in the Development of Essential Hypertension in Children and Young Adults. Ph.D. Dissertation, Med-ical Faculty Ljubljana, Ljubljana.</mixed-citation></ref><ref id="scirp.70039-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Falkner, B., Gidding, S.S., Portman, R. and Rosner, B. (2008) Blood Pressure Variability and Classification of Prehypertension and Hypertension in Adolescence. Pediatrics, 122, 238-242. http://dx.doi.org/10.1542/peds.2007-2776</mixed-citation></ref><ref id="scirp.70039-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Moore, W.E., Stephens, A., Wilson, T., Wilson, W. and Eichner, J.E. (2006) Body Mass Index and Blood Pressure Screening in a Rural Public School System: the Healthy Kids Project. Preventing Chronic Disease, 3, 1-10. http://www.cdc.gov/pcd/issues/2006/oct/05_0236.htm</mixed-citation></ref><ref id="scirp.70039-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Flynn, J. (2012) The Changing Face of Pediatric Hypertension in the Era of the Childhood Obesity Epidemic. Pediatric Nephrology, 28, 1059-1066. http://dx.doi.org/10.1007/s00467-012-2344-0</mixed-citation></ref><ref id="scirp.70039-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Kelley, G.A., Kelley, K.S. and Tran, Z.V. (2003) The Effects of Exercise on Resting Blood Pressure in Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials. Preventive Cardiology, 6, 8-16.http://dx.doi.org/10.1111/j.1520-037X.2003.01224.x</mixed-citation></ref><ref id="scirp.70039-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">He, F.J. and MacGregor, G.A. (2006) Importance of Salt in Determining Blood Pressure in Children: Meta-Analysis of Controlled Trials. Hypertension, 48, 861-869. http://dx.doi.org/10.1161/01.HYP.0000245672.27270.4a</mixed-citation></ref><ref id="scirp.70039-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Couch, S.C., Saelens, B.E., Levin, L., Dart, K., Falciglia, G. and Daniels, S.R. (2008) The Efficacy of a Clinic-Based Behavioral Nutrition Intervention Emphasizing a DASH-Type Diet for Adolescents with Elevated Blood Pressure. Journal of Pediatrics, 152, 494-501. http://dx.doi.org/10.1016/j.jpeds.2007.09.022</mixed-citation></ref><ref id="scirp.70039-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Williams, C.L., Hayman, L.L., Daniels, S.R., Robinson, T.N., Steinberger, J., Paridon, S., et al. (2002) Cardiovascular Health in Childhood. A Statement for Health Professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young. American Heart Association, Circulation, 106, 143-160. http://dx.doi.org/10.1161/01.cir.0000019555.61092.9e</mixed-citation></ref><ref id="scirp.70039-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Roberts, C.K. and Barnard, R.J. (2005) Effects of Exercise and Diet on Chronic Disease. Journal of Applied Physiology, 98, 3-30. http://dx.doi.org/10.1152/japplphysiol.00852.2004</mixed-citation></ref><ref id="scirp.70039-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Varon, J. (2008) Treatment of Acute Severe Hypertension. Drugs, 68, 283-297.http://dx.doi.org/10.2165/00003495-200868030-00003</mixed-citation></ref><ref id="scirp.70039-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Flynn, J.T. and Tullus, K. (2009) Severe Hypertension in Children and Adolescents: Pathophysiology and Treatment. Pediatric Nephrology, 24, 1101-1112. http://dx.doi.org/10.1007/s00467-008-1000-1</mixed-citation></ref><ref id="scirp.70039-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Lande, M.B. and Flynn, J.T. (2009) Treatment of Hypertension in Children and Adolescents. Pediatric Nephrology, 24, 1939-1949. http://dx.doi.org/10.1007/s00467-007-0573-4</mixed-citation></ref><ref id="scirp.70039-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Kavey, R.E.W., Simons-Morton, D. and Jesus, J.M. (2011) Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report. Pediatrics, 128, S213-S256.http://dx.doi.org/10.1542/peds.2009-2107C</mixed-citation></ref><ref id="scirp.70039-ref57"><label>57</label><mixed-citation publication-type="other" xlink:type="simple">Kavey, R.E.W., Daniels, S.R. and Flynn, J.T. (2010) Management of High Blood Pressure in Children and Adolescents. Cardiology Clinics, 28, 597-607. http://dx.doi.org/10.1016/j.ccl.2010.07.004</mixed-citation></ref><ref id="scirp.70039-ref58"><label>58</label><mixed-citation publication-type="other" xlink:type="simple">Falkner, B., Lurbe, E. and Schaefer, F. (2010) High Blood Pressure in Children: Clinical and Health Policy Implications. Journal of Clinical Hypertension, 12, 261-276. http://dx.doi.org/10.1111/j.1751-7176.2009.00245.x</mixed-citation></ref><ref id="scirp.70039-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Hong, Y.M. (2010) Atherosclerotic Cardiovascular Disease Beginning in Childhood. Korean Circulation Journal, 40, 1-9. http://dx.doi.org/10.4070/kcj.2010.40.1.1</mixed-citation></ref><ref id="scirp.70039-ref60"><label>60</label><mixed-citation publication-type="other" xlink:type="simple">Lloyd-Jones, D.M., Hong, Y., Labarthe, D., Mozaffarian, D., Appel, L.J., Van Horn, L., et al. (2010) American Heart Association Strategic Planning Task Force and Statistics Committee. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association’s Strategic Impact Goal through 2020 and beyond. Circulation, 121, 586-613. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192703</mixed-citation></ref><ref id="scirp.70039-ref61"><label>61</label><mixed-citation publication-type="other" xlink:type="simple">Urbina, E.M., Williams, R.V., Alpert, B.S., Collins, R.T., Daniels, S.R., Hayman, L., et al. (2009) Noninvasive Assessment of Subclinical Atherosclerosis in Children and Adolescents: Recommendations for Standard Assessment for Clinical Research: A Scientific Statement from the American Heart Association. Hypertension, 54, 919-950.http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.192639</mixed-citation></ref></ref-list></back></article>